Novogen (NASDAQ:KZIA) Earns Buy Rating from BTIG Research

Novogen (NASDAQ:KZIA)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a report released on Thursday, Benzinga reports. They currently have a $40.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 236.70% from the stock’s previous close.

KZIA has been the subject of several other reports. Lake Street Capital began coverage on shares of Novogen in a research note on Thursday, June 11th. They set a “buy” rating and a $32.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Finally, Canaccord Genuity Group initiated coverage on shares of Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 price target for the company. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Novogen has a consensus rating of “Moderate Buy” and an average target price of $27.33.

Novogen Trading Down 1.1%

NASDAQ KZIA opened at $11.88 on Thursday. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40. The business’s fifty day simple moving average is $13.19 and its 200-day simple moving average is $11.65.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.